SERPINC1 serpin family C member 1
ENSG00000117601 · protein coding · Open Targets profile
Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade (PubMed:15140129, PubMed:15853774). AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa (PubMed:15140129). Its inhibitory activity is greatly enhanced in the presence of heparin. .
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand, High-Quality Pocket, Druggable Family
- Antibody
- GO CC high conf, UniProt loc med conf, UniProt SigP or TMHMM
- PROTAC
- Small Molecule Binder
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 0.2767600119113922 (upper bound 0.448419988155365). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 400 registry trials, updated in the last three years, of the most advanced drugs against SERPINC1 (danaparoid, fondaparinux, heparin, tinzaparin, dalteparin, nadroparin calcium, heparin calcium, bemiparin, fitusiran), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Frank MP van HarenAustralian National University · 2 of 2 trials Phase 2+
- Marc CarrierOttawa Hospital Research Institute · 2 of 2 trials Phase 2+
- Zhejie LiuSecond Affiliated Hospital, Zhejiang University, School of Medicine · 2 of 2 trials Phase 2+
- Dapeng MoBeijing Tiantan Hospital · 1 of 2 trials Phase 2+
- Li SunGuizhou Provincial Peoples Hospital · 1 of 2 trials Phase 2+
- Zhongrong MiaoBeijing Tiantan Hospital · 1 of 2 trials Phase 2+
- Afshan HameedUniversity of California, Irvine · 1 of 1 trials Phase 2+
- Agnes Y. Y. LeeDirector of Thrombosis, Division of Hematology, University of British Columbia, Canada · 1 of 1 trials Phase 2+
- Ahmad Uzair QureshiMayo Hospital Lahore · 1 of 1 trials Phase 2+
- Ajay KirtaneColumbia University · 1 of 1 trials Phase 2+
- Alain LeizoroviczFaculté de Médecine Laënnec · 1 of 1 trials Phase 2+
- Alexis TurgeonL'Universite Laval · 1 of 1 trials Phase 2+
- Amira AdlyFaculty of Medicine Ain Shams University · 1 of 1 trials Phase 2+
- Amit SinglaRutgers University · 1 of 1 trials Phase 2+
- Anders AnemanSydney WAHS · 1 of 1 trials Phase 2+
Registry trials of danaparoid, fondaparinux, heparin, tinzaparin, dalteparin, nadroparin calcium, heparin calcium, bemiparin, fitusiran updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 322 of 373 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 27 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
237 trials of drugs against SERPINC1 were stopped early; 18 of the 200 most recent give no reason
Terminated, withdrawn and suspended interventional trials of danaparoid, fondaparinux, heparin, tinzaparin, dalteparin, nadroparin calcium, heparin calcium, bemiparin, fitusiran, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 237.
- terminated · 2026-10-28 · Consorci Sanitari de l'Alt Penedès i Garraf · Low dose heparin“Poor recruitment”
- terminated · 2026-10-26 · Ottawa Hospital Research Institute · matched by the registry's drug synonyms“Study was stopped prematurely because of poor accrual.”
- terminated · 2026-10-22 · Oslo University Hospital · matched by the registry's drug synonyms“Following temporary halt of inclusion in September 2024, several measures were taken, as previuosly reported. As numbers included by September 2024 were sufficient to conclude for primary endpont, we have decided not to restart the trial.”
- withdrawn · 2026-09-17 · H. Lee Moffitt Cancer Center and Research Institute · matched by the registry's drug synonyms“study no longer proceeding”
- withdrawn · 2026-07-15 · Wake Forest University Health Sciences · matched by the registry's drug synonyms“Changes in within study team. No participants enrolled.”
- terminated · 2026-06-25 · OHSU Knight Cancer Institute · matched by the registry's drug synonyms“change in standard-of-care systemic therapy”
- terminated · 2026-06-24 · SHI Jia · matched by the registry's drug synonyms“At a meeting on February 17, 2025, the Data and Safety Monitoring Board recommended early termination because the predefined efficacy boundary was crossed.”
- terminated · 2026-06-12 · University Hospital, Montpellier · Heparin“Difficulty of inclusion”
- terminated · 2026-06-08 · Weill Medical College of Cornell University · matched by the registry's drug synonyms“Study terminated due to low accrual”
- withdrawn · 2026-04-20 · ExThera Medical Corporation · matched by the registry's drug synonyms“ExThera was not the sponsor. No patients were enrolled.”
- terminated · 2026-04-17 · Anthos Therapeutics, Inc. · Dalteparin“Sponsor Decision”
- withdrawn · 2026-04-06 · Assistance Publique - Hôpitaux de Paris · matched by the registry's drug synonyms“The study was terminated following revisions to the diagnostic criteria defining the target pathology, which significantly impacted the study design”
- terminated · 2026-04-01 · Jocelyn Fitzgerald · matched by the registry's drug synonyms“unable to reach the recruitment numbers required to power our primary outcome”
- terminated · 2026-02-23 · Anthos Therapeutics, Inc. · matched by the registry's drug synonyms“Sponsor decision”
- terminated · 2026-02-03 · Urigen · Heparin“Prematurely terminated due to data inconsistent with the experimental plan and lack of funding”
- terminated · 2025-11-25 · Veralox Therapeutics · matched by the registry's drug synonyms“Veralox Therapeutics Business Decision.”
- terminated · 2025-11-17 · Shanghai Hengrui Pharmaceutical Co., Ltd. · matched by the registry's drug synonyms“Adjustment of the sponsor's R\&D strategy”
- terminated · 2025-07-24 · MediSys Health Network · matched by the registry's drug synonyms“Unable to resume the study due to patient billing issues. No actual clinical reason.”
- terminated · 2025-05-31 · Stephen Esper · matched by the registry's drug synonyms“A new standard of care was introduced making it impossible to continue with the study. Additionally, some of the blood product and transfusion related outcomes were not collected because this data was not present in the EMR.”
- withdrawn · 2025-02-10 · Paulo Brofman · matched by the registry's drug synonyms“No patient could be included because there was a decrease in the number of patients with complications due to COVID-19. Also, a Brazilian government agency approved this clinical trial, and the project execution period ended in March 2023.”
- terminated · 2025-02-06 · Dijklander Ziekenhuis · ACT guided heparinization, 5 000 IU of heparin“Futility”
- suspended · 2025-01-16 · Ohio State University · matched by the registry's drug synonyms“Pausing of allotransplant program due to logistic issues.”
- terminated · 2025-01-07 · Pirogov Russian National Research Medical University · matched by the registry's drug synonyms“Lack of the eligible patients”
- withdrawn · 2024-11-29 · Mario Negri Institute for Pharmacological Research · matched by the registry's drug synonyms“authorization denied”
- terminated · 2024-10-18 · Fernando Sanchez · Heparin sodium“Enrollment slower than anticipated and interrupted by COVID-19 pandemic”
Paediatric incentives and obligations for SERPINC1's drugs
For danaparoid, fondaparinux, heparin, tinzaparin, dalteparin, nadroparin calcium, heparin calcium, bemiparin, fitusiran: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · SERPINC1 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMA/PE/0000242247 (fitusiran, Treatment of congenital haemophilia A;Treatment of congenital haemophilia B): PM: decision on the application for modification of an agreed PIP, 13 Jun 2025; EMEA-002885-PIP01-20 (heparin sodium, Prevention of thromboembolic events;Treatment of thromboembolic events): W: decision granting a waiver in all age groups for all conditions or indications, 29 Jan 2021; EMEA-002557-PIP01-19 (heparin (sodium), Prevention of thromboembolic events): W: decision granting a waiver in all age groups for all conditions or indications, 16 Jul 2019Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/14/1297 positive 29 Jul 2014: Treatment of haemophilia A; EU/3/14/1298 positive 29 Jul 2014: Treatment of haemophilia B; EU/3/06/371 positive 22 May 2006: Treatment of cystic fibrosis; EU/3/04/223 withdrawn 2 Sept 2004: Treatment of idiopathic pulmonary fibrosis; +1 moreRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Arixtra: authorised since 20 Mar 2002; Quixidar: withdrawn since 21 Mar 2002Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of danaparoid, fondaparinux, heparin, tinzaparin, dalteparin, nadroparin calcium, heparin calcium, bemiparin, fitusiranRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 157 interventional studies of danaparoid, fondaparinux, heparin, tinzaparin, dalteparin, nadroparin calcium, heparin calcium, bemiparin, fitusiran include patients under 18; 27 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 12 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.